Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation

Leukemia and Lymphoma

Volumn 51, Issue 1, 2010, Pages 146-148

  Cavattoni, Irene ^a,b   Zabelina, Tatjana ^a   Ayuk, Francis ^a   Wolschke, Christine ^a   Bacher, Ulrike ^a   Zander, Axel ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Regional Hospital Bozen   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLUDARABINE; MELPHALAN; RITUXIMAB; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; GRAFT VERSUS LYMPHOMA EFFECT; HAIRY CELL LEUKEMIA; HUMAN; LARGE CELL LYMPHOMA; LETTER; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOCYTES; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 74949106759     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903275594     Document Type: Letter

References (13)

1. Vigouroux S,MichalletM, PorcherR, et al. Long-termoutcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).Haematologica 2007;92:627-634.
2. Escalón MP, Champlin RE, Saliba RM, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004;22:2419-2423.
3. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003;32:1159-1163.
4. Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:50-58.
5. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423.
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.NEngl J Med 2002;346:235-242.
7. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large- B-cell: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7: 3379-3391.
8. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004;32:28-35.
9. Kamble R, Oholendt M, Carrum G. Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2006;12:1201-1202.
10. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroidrefractory chronic graft-versus-host disease. Blood 2006;108:756-762. (Pubitemid 44061381)
11. Hasegawa M, Hamaguchi Y, Yanaba K, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954-966.
12. Pfeiffer M, Stanojevic S, Feuchtinger T, et al. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Bone Marrow Transplant 2005;36:91-97.
13. Shimoni A, Hardan I, Avigdor A, et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non- Hodgkin's lymphoma. Br J Haematol 2003;122:457-464.